FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1411-1412 April 7, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

On April 12, 1955, Jonas Salk's polio vaccine — made by inactivating poliovirus with formaldehyde — was declared to be safe and effective. The trial of Salk's vaccine had included 1.8 million children who were inoculated with either vaccine (made by either Eli Lilly or Parke-Davis) or placebo or were not inoculated but only observed. That afternoon, an advisory committee to the Laboratory of Biologics Control (the federal agency that was responsible for licensing biologic products in the United States) recommended that licenses to produce the vaccine be granted to five pharmaceutical companies: Eli Lilly, Parke-Davis, Wyeth, Pitman-Moore, and Cutter. . . . [Full Text of this Article]

Source Information

Dr. Offit is chief of the Division of Infectious Diseases, Children's Hospital of Philadelphia, and a professor of pediatrics at the University of Pennsylvania School of Medicine, Philadelphia.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.